DGS Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

DGS Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$330K	Buy	10,945 +156	+1%	+$5.02K	0.05%	361
2025 Q4	$337K	Buy	10,789 +52	+0.5%	+$1.28K	0.06%	292
2025 Q3	$217K	Sell	10,737 -1,343	-11%	-$23.6K	0.04%	374
2025 Q2	$202K	Sell	12,080 -1,650	-12%	-$26.6K	0.04%	324
2025 Q1	$211K	Sell	13,730 -1,610	-10%	-$28.8K	0.06%	280
2024 Q4	$338K	Buy	15,340 +1,713	+13%	+$31.2K	0.08%	206
2024 Q3	$246K	Buy	13,627 +872	+7%	+$15.3K	0.07%	245
2024 Q2	$207K	Buy	12,755 +1,175	+10%	+$18.1K	0.06%	260
2024 Q1	$163K	Buy	11,580 +191	+2%	+$2.41K	0.05%	274
2023 Q4	$119K	Buy	+11,389	New	+$106K	0.05%	238
2023 Q2	–	Sell	-14,047	Closed	-$124K	–	258
2023 Q1	$124K	Sell	14,047 -1,204	-8%	-$11.9K	0.07%	204
2022 Q4	$139K	Buy	15,251 +4,327	+40%	+$37.8K	0.09%	204
2022 Q3	$88.2K	Buy	+10,924	New	+$96.6K	0.06%	193
2022 Q2	–	Sell	-15,611	Closed	-$147K	–	221
2022 Q1	$147K	Buy	+15,611	New	+$130K	0.09%	179

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DGS Capital Management's TEVA Position: Q1 2026 in Review

DGS Capital Management increased its Teva Pharmaceuticals (TEVA) stake by 1.4% in Q1 2026, buying an estimated $5.02K and bringing the position to 10,945 shares worth $330K. The position accounts for 0.05% of the portfolio, ranked #361.

DGS Capital Management first reported a position in TEVA in Q1 2022 and has held it in 14 quarters since. The position peaked at $338K in Q4 2024. 652 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

DGS Capital Management held 10,945 shares of Teva Pharmaceuticals worth $330K as of Q1 2026.
DGS Capital Management bought 156 Teva Pharmaceuticals shares in Q1 2026, an estimated $5.02K.
Teva Pharmaceuticals made up 0.05% of DGS Capital Management's portfolio in Q1 2026, its #361 holding.
DGS Capital Management first reported a position in Teva Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
DGS Capital Management's Teva Pharmaceuticals position peaked at $338K in Q4 2024.
652 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on DGS Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.